tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Roden, 12 are a BUY (92.31%), 1 are a HOLD (7.69%).
Analyst Matthew Roden, carries an average stock price target met ratio of 95.48% that have a potential upside of 28.74% achieved within 396 days. Previously, Matthew Roden worked at UBS.
Matthew Roden’s has documented 98 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on GILD, Gilead Sciences at 29-Apr-2016.
Analyst best performing recommendations are on CELG (CELGENE).
The best stock recommendation documented was for CELG (CELGENE) at 6/30/2015. The price target of $130 was fulfilled within 15 days with a profit of $14.27 (12.33%) receiving and performance score of 8.22.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$101
$-7.24 (-6.69%)
$101
5 years 6 months 12 days ago
(31-Oct-2019)
2/8 (25%)
$-7.53 (-6.94%)
171
Hold
$115
$6.76 (6.25%)
$102
5 years 6 months 12 days ago
(31-Oct-2019)
3/12 (25%)
$6.47 (5.96%)
382
Hold
$100
$-8.24 (-7.61%)
$128
5 years 8 months 24 days ago
(18-Aug-2019)
3/6 (50%)
$4.78 (5.02%)
159
Buy
$102
$-6.24 (-5.76%)
$105
6 years 10 days ago
(02-May-2019)
4/4 (100%)
$5.12 (5.28%)
207
Hold
$100
$-8.24 (-7.61%)
$100
6 years 1 months 8 days ago
(04-Apr-2019)
2/7 (28.57%)
$5.2 (5.49%)
282
What Year was the first public recommendation made by Matthew Roden?
